Enovis (NYSE:ENOV) Stock Price Expected to Rise, BTIG Research Analyst Says

Enovis (NYSE:ENOV) had its target price lifted by equities research analysts at BTIG Research from $41.00 to $43.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. BTIG Research’s price objective suggests a potential upside of 71.89% from the company’s previous close.

A number of other equities research analysts have also commented on the stock. UBS Group reissued a “buy” rating and set a $50.00 price objective on shares of Enovis in a report on Monday, January 5th. Wells Fargo & Company boosted their price objective on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Evercore reiterated an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. Finally, Canaccord Genuity Group cut their price target on Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, December 17th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

Enovis Price Performance

Enovis stock traded up $2.70 during trading hours on Thursday, hitting $25.02. 1,470,283 shares of the stock were exchanged, compared to its average volume of 1,124,407. Enovis has a 12 month low of $21.00 and a 12 month high of $40.69. The business’s 50-day moving average is $24.34 and its two-hundred day moving average is $28.23. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.16 and a current ratio of 2.22. The stock has a market capitalization of $1.43 billion, a P/E ratio of -1.06 and a beta of 1.52.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. Enovis had a positive return on equity of 7.79% and a negative net margin of 61.22%.The business had revenue of $575.76 million for the quarter, compared to analyst estimates of $584.30 million. During the same period in the prior year, the company earned $0.98 EPS. Enovis’s revenue for the quarter was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities research analysts expect that Enovis will post 2.79 EPS for the current fiscal year.

Insider Buying and Selling

In other Enovis news, EVP Daniel A. Pryor sold 999 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total transaction of $27,172.80. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ENOV. Arax Advisory Partners bought a new position in Enovis during the fourth quarter worth $29,000. Farther Finance Advisors LLC boosted its holdings in shares of Enovis by 42.8% during the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after acquiring an additional 367 shares during the period. EverSource Wealth Advisors LLC increased its stake in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. Elevation Point Wealth Partners LLC acquired a new stake in Enovis during the 2nd quarter worth approximately $46,000. Finally, SJS Investment Consulting Inc. lifted its holdings in shares of Enovis by 30,340.0% during the third quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock worth $46,000 after buying an additional 1,517 shares in the last quarter. 98.45% of the stock is owned by institutional investors and hedge funds.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.